Drug addiction: a critical problem calling for novel solutions.
Tyndale
R
R
D001552:Benzazepines / Q000627:therapeutic use; D002047:Buprenorphine / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D002908:Chronic Disease; D005380:Financing, Government; D005820:Genetic Testing; D040261:Harm Reduction; D006801:Humans; D008385:Marijuana Smoking; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D015995:Prevalence; D018907:Privacy; D011810:Quinoxalines / Q000627:therapeutic use; D011978:Receptors, Nicotinic / Q000187:drug effects; D012008:Recurrence; D012309:Risk-Taking; D012907:Smoking / Q000191:economics / Q000453:epidemiology; D016540:Smoking Cessation / Q000191:economics*; D000074606:Smoking Prevention; D012931:Social Environment; D019966:Substance-Related Disorders / Q000191:economics / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D000068580:Varenicline
D001552:Benzazepines; D009292:Narcotic Antagonists; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D016642:Bupropion; D002047:Buprenorphine; D009271:Naltrexone; D000068580:Varenicline